AI MARKET SCANNING

Upstream Bio Inc

📅 Next Catalyst: Nov 04, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP -1.97%
MAX GAP RECORD -10.93%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $UPB
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 04, 2026 Earnings Release 2026-11-04 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 11, 2026 Earnings Release 2026-08-11 (BEFORE OPEN)
+0.54%
May 13, 2026 Earnings Release 2026-05-13 (BEFORE OPEN)
+0.11%
Mar 26, 2026 Earnings Release 2026-03-26 (AFTER CLOSE)
-10.93%
Nov 05, 2025 Earnings Release 2025-11-05 (BEFORE OPEN)
+1.60%
Aug 06, 2025 Earnings Release 2025-08-06 (BEFORE OPEN)
-2.00%
May 06, 2025 Earnings Release 2025-05-06 (BEFORE OPEN)
-1.27%
Nov 07, 2024 Earnings Release 2024-11-07 (BEFORE OPEN)
-1.81%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.6%
Bullish Gaps (1)
Bearish Gaps (4)
Neutral / Flat (2)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $UPB

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It develops verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin. The company was founded in…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗